The CSL Limited (ASX: CSL) share price is flat at $198.60 today after the $90 billion healthcare giant gave a presentation to investors on the progress of its Seqirus influenza vaccine business at a Macquarie Group Ltd (ASX: MQG) organised equities conference in Sydney.
The flu business is seasonal as most patients receive their flu jabs in the northern hemisphere’s autumn period ahead of the winter flu season and the below slide shows how Seqirus grew revenue 21% over the first half of fiscal 2019.
Total CSL revenue over the first half of fiscal 2019 was US$4,505 million so we can see that Seqirus at US$949 million is a significant and fast-growing profit driver for the business for its interim results.
However, it should be noted that over the second half the fixed cost base and lack of demand may result in Seqirus posting a loss for now.
Thanks to its multiple operating arms delivering consistent growth CSL remains one of the best looking blue-chip shares on the ASX, alongside its host today Macquarie Group.
A little-known ASX company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.
And make no mistake – it is coming. To the tune of an estimated $US22 billion.
Cannabis legalisation is sweeping over North America, and full legalisation arrived in Canada in October 2018.
Here's the best part: we think there's one ASX stock that's uniquely positioned to profit immensely from this explosive new industry... taking savvy investors along for what could be one heck of a ride.
AND, this is the first time The Motley Fool Australia has EVER put a BUY recommendation on a marijuana stock.
- NEW: Free report names top 3 ASX dividend shares to buy for 2019
- Top analysts name their top 3 ASX blue chip shares for 2019
- Richest man alive issues dire warning
- 3 quality dividend shares to boost your income
Tom Richardson owns shares of CSL Ltd and Macquarie. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd and Macquarie. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2019